Fenofibrate IN JAUNDICE OF HEALTHY NEWBORN

Study of Efficacy of Fenofibrate in Neonatal Hyperbilirubinemia - FEBIN

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2016/07/007069

Enrollment

Registered

2016-07-11

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- NEONATAL HYPERBILIRUBINEMIA Health Condition 2: P589- Neonatal jaundice due to excessivehemolysis, unspecified

Interventions

Intervention1: FENOFIBRATE WITH PHOTOTHERAPY: 100mg/kg/dose WITH PHOTOTHERAPY Single dose on the first day Control Intervention1: PHOTOTHERAPY: PHOTOTHERAPY

Eligibility

Inclusion criteria

Inclusion criteria: FULL TERM NEONATE WITH UNCONJUGATED HYPERBILIRUBINEMIA

Exclusion criteria

Exclusion criteria: LBW NEWBORNS WITH SEPTICEMIA NEWBORNS HAVING EITHER ABO OR RH INCOMPATIBILITY NEWBORNS HAVING DIRECT HYPERBILIRUBINEMIA >2MG/DL OR >15% OF TSB G6PD DEFICIENCY OR HYPOTHYROIDISM

Design outcomes

Primary

Measure	Time frame
CHANGE IN TOTAL SERUM BILIRUBINTimepoint: 0 HOUR 24 HOUR 48 HOUR	—

Secondary

Measure	Time frame
DURATION OF HOSPITALIZATIONTimepoint: 48 hour	—

Countries

India

Contacts

Public ContactDR JAYENDRA GOHIL

GOVT. MEDICAL COLLEGE BHAVNAGAR

drjayendragohil@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026